Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10852
Peer-review started: January 13, 2022
First decision: June 15, 2022
Revised: June 23, 2022
Accepted: August 13, 2022
Article in press: August 13, 2022
Published online: October 26, 2022
Processing time: 280 Days and 11.2 Hours
The pursuit of this paper is to collect principal reviews and systematic reviews about hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) used in colorectal cancer (CRC). We focus on principal biological aspects of CRC, hyperthermia effects, and surgical procedures. We searched PubMed/MEDLINE for the principal reviews and systematic reviews published from 2010 to 2021 regarding the bimodal treatment (CRS + HIPEC) against local and advanced CRC. In the literature, from several studies, it seems that the efficacy of bimodal treatment with an accurate CRS can extend overall survival. Despite these studies, there are not still any straight guidelines more detailed and scheduled about the use of combined treatment in patients with CRC. Even if the concept is still not very clear and shared, after a careful evaluation of the published data, and after some technical and pathophysiological descriptions, we concluded that it is possible to improve the overall survival and quality of life and to reduce the tumor relapse in patients affected by locally advanced (pT4) CRC with peritoneal metastases.
Core Tip: The purpose of this review is to summarize the most relevant evidence on the use of hyper